



Advances in Treatment of Urinary Bladder Cancer

Guest Editor:

Dr. Amir M. Sherif

Department of Surgical and
Perioperative Sciences, Urology
and Andrology, Umeå University,
901 85 Umeå, Sweden

Deadline for manuscript
submissions:

closed (15 May 2024)

Message from the Guest Editor

Urinary bladder cancer is among the top ten most common cancer types in the world, with approximately 550,000 new cases annually. At present, 75% of cases are non-muscle-invasive bladder cancer (NMIBC), and the others are muscle-invasive (MIBC), a progression from the first kind. The identification of targets and potential biomarkers based on genomic sequencing analyses can also be useful for predicting the response of novel therapeutic strategies. Therapy has in recent years evolved from surgery to oncological combination therapies, and more recently, immunotherapeutic strategies have been added to the treatment arsenal.

This Special Issue aims to present new and innovative approaches and results relating to basic science, translational research, and epidemiology in the field of urinary bladder cancer. The scope entails studies on non-muscle-invasive urinary bladder cancer (NMIBC) as well as those on muscle invasive urinary bladder cancer (MIBC) and papers investigating molecular biomarkers' response to treatment and radiomics to improve staging in urinary bladder cancer. We welcome original articles and review papers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)